ArticleFoods (Basel, Switzerland)2025
Network Pharmacology and Experimental Validation Reveal Therapeutic Potential of Propolis in UV-Induced Allergic Dermatitis.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Propolis demonstrates diverse pharmacological properties encompassing antimicrobial, anti-inflammatory, antioxidant, immunomodulatory, and wound-healing activities. This study investigated the therapeutic mechanism of propolis against ultraviolet (UV)-induced allergic dermatitis through an integrated approach combining network pharmacology with in vitro experimental validation. The targets of propolis components were conducted through the PubChem, the EMBL-EBI, and SEA Search Server databases, and the disease-associated targets for atopic dermatitis and related allergic conditions were extracted from GeneCards. The overlapping targets between propolis components and UV-induced dermatitis were screened. The Gene Ontology (GO) Enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed. The key targets were further validated through ELISA experiments using HSF cells. The results show that there were 28 overlapping targets between propolis and UV-induced allergic dermatitis. The GO enrichment results show that there were 1246 terms of biological functions, 52 terms of cellular components, and 98 terms of molecular functions. KEGG pathway enrichment obtained 110 signaling pathways. The protein-protein interaction (PPI) network showed that TNF, NFKB1, MMP-9, and IL-2 were hub proteins. The ELISA experiment confirmed that propolis reduced the levels of MMP-9 and IL-2 in UBV-induced allergic dermatitis of HSF cells in a dose-dependent manner. These findings provide mechanistic evidence supporting propolis as a promising functional food, dietary supplements, or medicinal agent for UV-induced allergic skin disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.